SAN FRANCISCO, March 10, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in NantHealth, Inc. (NASDAQ:NH) to the IPO-related securities class action pending in the U.S. District Court for the Central District of California and to the May 6, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of NH (1) pursuant and/or traceable to the Company’s registration statement and prospectus issued in connection with the Company’s initial public offering on or about June 1, 2016, or (2) between June 1, 2016 and March 6, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/NH
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On March 6, 2017, STATnews published a report entitled “How the world’s richest doctor gave away millions – then steered the cash back to his company.” The report stated that the NantHealth’s founder Patrick Soon-Shiong (“Dr. Soon”) made a $12 million gift to the University of Utah that required the University to spend $10 million for NantHealth’s genetic sequencing work.
The report also stated: “[T]he deal made it possible for [NantHealth] to inflate, by more than 50 percent, the number of test orders it reported to investors late last year while updating them on interest in a flagship product, a diagnostic tool known as GPS Cancer. Soon-Shiong’s team counted genetic sequencing ordered by the University of Utah in those order numbers – even though the work for the university did not have anything to do with diagnosing or recommending treatments for cancer patients.”
This news drove the price of NantHealth shares down approximately 23% to close at $5.50 per share on March 6, 2017.
“We’re focused on management’s earlier tally given to investors in comparison to the recent news that, if true, would appear to contradict those statements,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding NantHealth should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 



